Acute Myeloid Leukemia Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Otsuka Pharma, Genentech, Inc., Sanofi, AbbVie

Acute Myeloid Leukemia Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Otsuka Pharma, Genentech, Inc., Sanofi, AbbVie
DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Myeloid Leukemia.

DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Acute Myeloid Leukemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Myeloid Leukemia Market Forecast

 

Some of the key facts of the Acute Myeloid Leukemia Market Report: 

  • The Acute Myeloid Leukemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of acute myeloid leukemia was 4.3 per 100,000 men and women per year in the United States
  • According to the Cancer Research UK, Acute Myeloid Leukemia incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2016-2018, on average each year more than 4 in 10 new cases (42%) were in people aged 75 and over
  • Key Acute Myeloid Leukemia Companies: Otsuka Pharmaceutical Co., Ltd., Genentech, Inc., Sanofi, AbbVie, Clavis Pharma, AstraZeneca, Astex Pharmaceuticals, Inc., BioSight Ltd., Novartis, Gilead Sciences, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Orca Bio, Gilead Sciences, GlycoMimetics Incorporated, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others
  • Key Acute Myeloid Leukemia Therapies: ASTX727, Chimerix, IO-202, OCV-501, Azacitidine, clofarabine, Venetoclax, Elacytarabine, AZD1152, guadecitabine, BST-236, Uproleselan, Midostaurin, Magrolimab, TCB008, Dociparastat, ADI-PEG, Cytarabine, and others
  • The Acute Myeloid Leukemia epidemiology based on gender analyzed that acute myeloid leukemia (AML) is more prominent in males in comparison to females
  • The Acute Myeloid Leukemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics.

 

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukaemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.

 

Get a Free sample for the Acute Myeloid Leukemia Market Report 

https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market

 

Acute Myeloid Leukemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acute Myeloid Leukemia Epidemiology Segmentation:

The Acute Myeloid Leukemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Acute Myeloid Leukemia
  • Prevalent Cases of Acute Myeloid Leukemia by severity
  • Gender-specific Prevalence of Acute Myeloid Leukemia
  • Diagnosed Cases of Episodic and Chronic Acute Myeloid Leukemia

 

Download the report to understand which factors are driving Acute Myeloid Leukemia epidemiology trends @ Acute Myeloid Leukemia Epidemiology Forecast

 

Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Myeloid Leukemia market or expected to get launched during the study period. The analysis covers Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Myeloid Leukemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Acute Myeloid Leukemia Therapies and Key Companies

  • ASTX727: Astex Pharmaceuticals
  • Chimerix: Dociparstat Sodium
  • IO-202: Immune Onc

 

Discover more about therapies set to grab major Acute Myeloid Leukemia market share @ Acute Myeloid Leukemia Treatment Market

 

Scope of the Acute Myeloid Leukemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Acute Myeloid Leukemia Companies: Otsuka Pharmaceutical Co., Ltd., Genentech, Inc., Sanofi, AbbVie, Clavis Pharma, AstraZeneca, Astex Pharmaceuticals, Inc., BioSight Ltd., Novartis, Gilead Sciences, Takeda Oncology, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Orca Bio, Gilead Sciences, GlycoMimetics Incorporated, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others
  • Key Acute Myeloid Leukemia Therapies: ASTX727, Chimerix, IO-202, OCV-501, Azacitidine, clofarabine, Venetoclax, Elacytarabine, AZD1152, guadecitabine, BST-236, Uproleselan, Midostaurin, Magrolimab, TCB008, Dociparastat, ADI-PEG, Cytarabine, and others
  • Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
  • Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Acute Myeloid Leukemia Unmet Needs, KOL’s views, Analyst’s views, Acute Myeloid Leukemia Market Access and Reimbursement 

 

To know more about Acute Myeloid Leukemia companies working in the treatment market, visit @ Acute Myeloid Leukemia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Acute Myeloid Leukemia Market Report Introduction

2. Executive Summary for Acute Myeloid Leukemia

3. SWOT analysis of Acute Myeloid Leukemia

4. Acute Myeloid Leukemia Patient Share (%) Overview at a Glance

5. Acute Myeloid Leukemia Market Overview at a Glance

6. Acute Myeloid Leukemia Disease Background and Overview

7. Acute Myeloid Leukemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Myeloid Leukemia 

9. Acute Myeloid Leukemia Current Treatment and Medical Practices

10. Acute Myeloid Leukemia Unmet Needs

11. Acute Myeloid Leukemia Emerging Therapies

12. Acute Myeloid Leukemia Market Outlook

13. Country-Wise Acute Myeloid Leukemia Market Analysis (2019–2032)

14. Acute Myeloid Leukemia Market Access and Reimbursement of Therapies

15. Acute Myeloid Leukemia Market Drivers

16. Acute Myeloid Leukemia Market Barriers

17.  Acute Myeloid Leukemia Appendix

18. Acute Myeloid Leukemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services


Posted

in

by

Tags: